United States Angiotensin II Receptor Blockers (ARBs) Industry 2025: Emerging Therapies, R&D Pipeline & Market Forecast

DataM Intelligence has published a new research report on "Angiotensin II Receptor Blockers Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/angiotensin-ii-receptor-blockers-market?kb

United States: Recent Industry Developments

✅ In September 2025, the FDA approved a new combination therapy involving Losartan for better hypertension management in patients with chronic kidney disease.

✅ In August 2025, Boehringer Ingelheim initiated a Phase III trial for its novel ARB targeting resistant hypertension in the U.S. population.

✅ In July 2025, Pfizer expanded its clinical studies for Valsartan formulations focusing on heart failure patients, aiming to improve adherence and outcomes.

✅ In June 2025, Novartis launched an educational program in U.S. hospitals to increase awareness of ARB therapies in cardiovascular risk reduction.

✅ In May 2025, Amgen reported positive real-world evidence on the safety profile of Irbesartan in diabetic patients with high cardiovascular risk.

Japan: Recent Industry Developments

✅ In September 2025, Takeda Pharmaceutical advanced a Phase III trial for Azilsartan, evaluating efficacy in elderly hypertensive patients.

✅ In August 2025, Daiichi Sankyo published long-term safety data of Olmesartan in Japanese post-marketing surveillance studies.

✅ In July 2025, Astellas Pharma introduced digital adherence tools to support patients on ARB therapy for hypertension and heart failure.

✅ In June 2025, Mitsubishi Tanabe Pharma expanded research on combination ARB therapies targeting patients with coexisting renal and cardiovascular conditions.

✅ In May 2025, Eisai initiated a real-world study to monitor blood pressure control and cardiovascular outcomes in Japanese patients using Valsartan.

Key Players:

Novartis AG, Daiichi Sankyo Co. Ltd, Lupin Ltd, Novartis AG, Takeda Pharmaceutical Co. Ltd, AstraZeneca, Sanofi S.A., Merck & Co., Inc., Boehringer Ingelheim, Abbive Inc and Zydus Cadila.

Key Development:

On March 26, 2024, Otsuka Pharmaceutical Co., Ltd. announced that Novartis Pharma K.K. received approval for Entresto Granular Tablets for Pediatric Use (12.5 mg / 31.25 mg; generic name: sacubitril valsartan sodium hydrate), an angiotensin receptor neprilysin inhibitor (ARNI).

On February 17, 2023, Travere Therapeutics, Inc. announced that the U.S. FDA granted accelerated approval to FILSPARI (spartan) for reducing proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progression, typically defined as a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.

Growth Forecast Projected:

The Global Angiotensin ii Receptor Blockers Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Angiotensin ii Receptor Blockers Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=angiotensin-ii-receptor-blockers-market

Key Segments:

By Type: (Valsartan, Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Others)

By Application: (Heart Failure, Hypertension, Kidney Disease, Others)

By End-Users: (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Angiotensin ii Receptor Blockers producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Angiotensin ii Receptor Blockers revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/angiotensin-ii-receptor-blockers-market?kb

FAQ's

Q1: How fast is the Angiotensin ii Receptor Blockers Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a High CAGR from 2025 to 2032

Q2: Which regions are dominating the Angiotensin ii Receptor Blockers Market and which are fastest-growing?

A: North America dominating the Angiotensin ii Receptor Blockers market.

Have any Query? Talk to our Expert @ https://www.datamintelligence.com/enquiry/angiotensin-ii-receptor-blockers-market

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.